OncoMatch/Clinical Trials/NCT06979596
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Is NCT06979596 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for malignant neoplasm.
Treatment: Opevesostat · Fludrocortisone/ Fludrocortisone acetate · Dexamethasone/Dexamethasone acetate · Rescue Medications · Fulvestrant · Exemestane · Megestrol acetate/Medroxyprogesterone acetate · Tamoxifen · Letrozole — Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prior therapy
Must have received: endocrine-based therapy — metastatic
Has experienced disease progression on or after at least 1 prior endocrine-based therapy in the metastatic setting.
Must have received: platinum-based chemotherapy — third-line (3L)
Has received between 4 to 8 cycles of platinum-based doublet chemotherapy in third-line (3L) setting for ovarian cancer.
Cannot have received:
Has platinum-resistant ovarian cancer (defined as disease that has progressed per radiographic imaging within 180 days after the last dose of first-line [1L] platinum-based therapy) or platinum-refractory ovarian cancer (defined as disease that has progressed per radiographic imaging while receiving or within 28 days of the last dose of 1L platinum based therapy).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Womens Cancer Care ( Site 0037) · Anchorage, Alaska
- Mount Sinai Cancer Center ( Site 0009) · Miami Beach, Florida
- TRIALS 365 ( Site 0022) · Shreveport, Louisiana
- Mary Lanning Healthcare ( Site 0019) · Hastings, Nebraska
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0021) · Hackensack, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify